drugset / Trial / NCT01363999

A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers

NCT01363999

Phase 1 Completed 24 enrolled Hoffmann-La Roche
RandomizedCrossoverOpen-labelTreatment

Summary

A single-center, crossover study to evaluate the pharmacokinetics of dalcetrapib and atorvastatin from prototype fixed dose combination formulations in healthy volunteers. Volunteers will receive a single dose of dalcetrapib with atorvastatin in each of four treatment periods.

Timeline

Start
2011-06
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule
Subject Dalcetrapib Small molecule

Indications

No indication recorded.